RPR's Maalox
This article was originally published in The Tan Sheet
Executive Summary
1992 worldwide sales of Rhone-Poulenc Rorer gastroenterology products -- essentially the Maalox line -- declined 7% to $ 303 mil., RPR says in its recently released 1992 annual report. U.S. sales "were below 1991 levels due to ongoing competitive challenges coupled with reductions in wholesaler inventory levels," the company reported. Maalox market share "showed improvement late in the second half of the year" benefiting from new promotional initiatives and the launches of Maalox HRF tablets and Maalox caplets. Sales grew in Europe, Canada and Japan, where Maalox Plus moved OTC.